Collectively, the data from this exploratory analysis suggest that ruxolitinib treatment (in randomized and crossover treatment arms) for up to 4 years provided progressive reductions in JAK2 p.V617F allele burden in patients with PV who were resistant to or intolerant of hydroxyurea. Here, JAK2 is linked to acquired polycythemia vera.